Literature DB >> 14978768

Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation.

Thomas Grunwald1, Finn Skou Pedersen, Ralf Wagner, Klaus Uberla.   

Abstract

BACKGROUND: Human gene therapy vectors based on primate lentiviruses harbour in contrast to oncoretroviruses the risk of vector mobilization by human immunodeficiency viruses (HIV). Infection of cells transduced with a lentiviral vector by HIV could lead to packaging of the lentiviral vector RNA into HIV particles and transfer of the vector.
METHODS: A new approach based on primer complementation was developed to reduce the risk of vector mobilization. The primer binding site (PBS) of an SIV-based vector was mutated abolishing tRNA primer binding and thus blocking reverse transcription. This block was efficiently by-passed during vector production by providing an artificial tRNA matching the mutated PBS with titers reaching 10(6) infectious units/ml.
RESULTS: Primer-complemented SIV vectors were mobilized from transduced cells by HIV-1 >150-fold less efficiently than vectors with wild-type PBS. Mobilization of the primer-complemented SIV vector by SIV was inhibited to a lesser extent indicating reduced efficacy of the primer complementation approach for preventing mobilization of lentiviral vectors by homologous virus. The analysis of the PBS of the vector DNA in target cells transduced with vectors containing mutated PBS in the absence of a matched tRNA suggests that formation of heterozygous particles followed by priming on the helper RNA and strand switch during reverse transcription can lead to mobilization of the primer-complemented vector by SIV, but not HIV-1. Although self-inactivating vectors were more efficient in preventing vector mobilization by HIV-1 than primer-complemented vectors, mobilization remained undectable only if both approaches were combined.
CONCLUSIONS: The primer complementation approach should further reduce the risk of mobilization of self-inactivating SIV-based vectors by HIV-1 and thus increase their safety. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978768     DOI: 10.1002/jgm.479

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  8 in total

1.  Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors.

Authors:  Hideki Hanawa; Derek A Persons; Arthur W Nienhuis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Viral determinants of integration site preferences of simian immunodeficiency virus-based vectors.

Authors:  Hella Monse; Stephanie Laufs; Seraphin Kuate; W Jens Zeller; Stefan Fruehauf; Klaus Uberla
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

Review 3.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

4.  Reduced mobilization of Rev-responsive element-deficient lentiviral vectors.

Authors:  Susann Lucke; Thomas Grunwald; Klaus Uberla
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Atraumatic oral spray immunization with replication-deficient viral vector vaccines.

Authors:  Christiane Stahl-Hennig; Seraphin Kuate; Monika Franz; You S Suh; Heribert Stoiber; Ulrike Sauermann; Klara Tenner-Racz; Stephen Norley; Ki S Park; Young C Sung; Ralph Steinman; Paul Racz; Klaus Uberla
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

Review 6.  Gene delivery by lentivirus vectors.

Authors:  Adam S Cockrell; Tal Kafri
Journal:  Mol Biotechnol       Date:  2007-07       Impact factor: 2.860

7.  Rev proteins of human and simian immunodeficiency virus enhance RNA encapsidation.

Authors:  Sabine Brandt; Maik Blissenbach; Bastian Grewe; Rebecca Konietzny; Thomas Grunwald; Klaus Uberla
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823

8.  Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides.

Authors:  Lars Steinstraesser; Bettina Tippler; Janine Mertens; Evert Lamme; Heinz-Herbert Homann; Marcus Lehnhardt; Oliver Wildner; Hans-Ulrich Steinau; Klaus Uberla
Journal:  Retrovirology       Date:  2005-01-18       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.